###### Strengths and limitations of this study

-   Large nationwide population-based study based on prospectively collected data from hospitals and general practices.

-   Comprehensive list of infections and antibiotics studied in people receiving their first treatment for type 2 diabetes.

-   Main limitation was possible residual confounding by differences in diabetes severity.

Introduction {#s1}
============

Glucose-lowering drugs (GLDs) are prescribed increasingly in patients with type 2 diabetes,[@R1] with the aim of reducing macrovascular and microvascular complications. Three out of four patients diagnosed with diabetes initiate pharmacotherapy within the following year.[@R2] Although infections are a major clinical problem and an important cause of death in patients with type 2 diabetes,[@R3] [@R4] population-based data are scarce on early infection risk in patients initiating GLD pharmacotherapy.

It has been observed recently that metformin use is associated with reduced risk of infections after surgery[@R5] and reduced risk of septicaemia,[@R6] with improved prognosis following septicaemia and other critical illness,[@R7] and with a beneficial effect on prevention and treatment of respiratory tract infections due to *Staphylococcus aureus*.[@R8] Limited epidemiological data are available comparing the association of different GLDs with risk of infections.[@R6] [@R9] In a Swedish study based on 51 675 patients with type 2 diabetes treated with GLDs between 2004 and 2007, the HR of hospitalisation for infection with co-occurrence of acidosis was greater for insulin monotherapy users (HR 1.37, 95% CI 1.26 to 1.50) and other oral GLDs users (80% sulfonylurea) (HR 1.16, 95% CI 1.04 to 1.28) compared with metformin users.[@R9] Another study of 43 015 cases with septicaemia and control participants nested in a cohort of newly diagnosed type 2 diabetes patients from Taiwan found that metformin use was associated with reduced risk of developing septicaemia (OR 0.80, 95% CI 0.77 to 0.83) compared with metformin non-users.[@R6] For other infections including those treated by general practitioners, comprehensive data on the risk among users of different GLDs are lacking.

Therefore, we undertook a large cohort study using nationwide Danish population data to investigate rates of community-based antibiotic use and hospital-treated infection associated with initiation of different GLDs in type 2 diabetes patients.

Methods {#s2}
=======

Data sources {#s2a}
------------

We used the Danish National Patient Registry (DNPR),[@R10] the Danish National Health Service Prescription Database (DNHSPD)[@R11] and the Danish Civil Registration System (CRS)[@R12] to conduct this study. The Danish National Health Service provides Danish residents with universal access to general practice and hospitals and reimburses most of the cost of prescription drugs, including GLDs.[@R11] We used the unique central personal registry (CPR) number to link individual-level data among registries. The CRS began to assign a CPR number to all residents at birth or upon immigration in 1968.[@R12] Since then, the CRS has maintained daily updated records of date of death or emigration, previous and current place of residence, marital status and CPR number for all Danish residents. The DNPR contains nationwide information on all hospitalisations since 1977 and on all outpatient and emergency room visits since 1995.[@R10] It records patients\' CPR number, a primary discharge diagnosis and up to 19 secondary discharge diagnoses coded according to the *International Classification of Diseases, Eighth Revision* (ICD-8) until the end of 1993, and *Tenth Revision* (ICD-10) thereafter. The DNHSPD collects data from all community pharmacies and hospital-based outpatient pharmacies. It has archived patient-related, drug-related and prescriber-related information on all prescription medications dispensed in Denmark since 2004.[@R11] The drugs are coded according to the Anatomical Therapeutic Chemical (ATC) classification system.

Study design and population {#s2b}
---------------------------

We conducted this population-based cohort study in a Danish nationwide cohort of patients with an incident type 2 diabetes diagnosis recorded between 1 January 2005 and 31 December 2012. Incident type 2 diabetes was defined as either the first record in the DNPR of a diabetes-associated inpatient admission (data available from 1977) or outpatient clinic contact (data available from 1995) or the first record of a GLD prescription in the DNHSPD (data available from January 2004), whichever came first.[@R13] To decrease the chance of including patients with type 1 diabetes, we restricted our cohort to patients who were 30 years or older when first diagnosed with diabetes (n=147 396).[@R14] We also excluded patients with a diabetes diagnosis but no recorded GLD prescription during the 2005--2012 study period (n=14 120). Women with a recorded diagnosis of polycystic ovarian disease who were using metformin monotherapy, identified from the DNPR and the DNHSPD, were excluded as well (n=1327). This left a final study cohort of 131 949 patients with incident pharmacotherapy for type 2 diabetes.

We defined exposure as the first record of a redeemed GLD prescription in the DNHSPD (the index date) between 2005 and 2012. We disregarded any change or addition of other GLD afterwards. We established seven mutually exclusive categories of exposure according to the type of first-prescribed GLD: metformin (biguanides); sulfonylurea; insulin; any fixed drug combinations; dipeptidyl peptidase-4 (DPP-4) inhibitors; glucagon-like peptidase-1 (GLP-1) analogue; meglitinides; other (including thiazolidinediones; and α glucosidase inhibitors) (see online [supplementary appendix](#SM1){ref-type="supplementary-material"} 1 for ATC codes). We followed the study cohort from the index date until death, emigration or end of the study period (31 December 2012), whichever came first.
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Assessment of outcomes {#s2c}
----------------------

Our outcomes were hospital-treated infections and community-based antibiotic use. Hospital-treated infection was defined as any first inpatient admission or outpatient hospital clinic contact associated with a primary or secondary discharge diagnosis of infection after the index date. We further divided hospital-treated infections into subcategories (see online [supplementary appendix](#SM1){ref-type="supplementary-material"} 1 for categories and associated ICD codes).

Community-based antibiotic use was defined as any first record of an antibiotic prescription in the DNHSPD that was redeemed during the study period after the index date. We investigated 10 groups of antibiotics prescribed to treat specific infections according to national Danish guidelines for general practitioners (see online [supplementary appendix](#SM1){ref-type="supplementary-material"} 1 for ATC codes).[@R15] [@R16]

Assessment of covariates {#s2d}
------------------------

We searched the DNPR for information on 19 major comorbidities included in the Charlson comorbidity index (CCI),[@R17] based on each cohort member\'s entire hospital contact history during the 10 years prior to his/her index date. We defined three comorbidity levels: low (CCI score of 0), medium (CCI scores of 1 or 2) and high (CCI score ≥3).[@R18] We also collected information on other covariates associated with risk of infection: microvascular and macrovascular diabetes complications not included in the CCI (see online [supplementary appendix](#SM1){ref-type="supplementary-material"} 1); diabetes duration (if a hospital diagnosis was present before the GLD initiation/index date); presence of alcoholism-related disorders (yes/no); a hospital diagnosis of obesity (yes/no); use of immunosuppressive drugs (yes/no), oral corticosteroids (yes/no) or statins (yes/no); marital status as a marker of social support (married/never married/divorced/widowed); and calendar period of inclusion (2005--2008/2009--2012).

Statistical analysis {#s2e}
--------------------

We described cohort characteristics at the time the first GLD was redeemed according to GLD categories ([table 1](#BMJOPEN2016011523TB1){ref-type="table"}). We used an intention-to-treat approach[@R19] and computed incidence rates (IRs) separately for community-based antibiotic use and for hospital-treated infections, by dividing the number of incident outcome events by total exposed patient-time during follow-up (expressed per 1000 patient-years at risk (PYAR)). We then used the Cox regression to compute HRs of community-based antibiotic use and hospital-treated infections (with 95% CIs) associated with the exposure categories described above, using metformin initiation as reference. We computed estimates adjusted for age and sex (Model 1) and estimates fully adjusted for all available confounders (Model 2) (see above). We repeated the analyses for specific infections and antibiotic groups, except for those associated with four or fewer events during complete follow-up.

###### 

Baseline characteristics of 131 949 patients with type 2 diabetes, according to initial pharmacotherapy with glucose-lowering drugs (2005--2012)

  Characteristics                                                     Metformin        Sulfonylurea     Insulin            Fixed drug combinations   DPP-4 inhibitors   GLP-1 analogues   Meglitinides     Other            Total
  ------------------------------------------------------------------- ---------------- ---------------- ------------------ ------------------------- ------------------ ----------------- ---------------- ---------------- ----------------
  *n* (%)\*                                                           106 424 (81)     16 703 (13)      7293 (6)           553 (\<1)                 358 (\<1)          295 (\<1)         231 (\<1)        92 (\<1)         131 949 (100)
  Sex                                                                                                                                                                                                                       
   Men                                                                59 213 (56)      9879 (59)        4421 (61)          355 (64)                  212 (59)           126 (43)          128 (55)         57 (62)          74 391 (56)
   Women                                                              47 211 (44)      6824 (41)        3872 (39)          198 (36)                  146 (41)           169 (57)          103 (45)         35 (38)          57 558 (44)
  Age in years                                                                                                                                                                                                              
   Median age (IQR)                                                   62 (52, 70)      67 (57, 76)      56 (43, 68)        62 (52, 70)               67 (56, 76)        52 (44, 61)       62 (53, 72)      58 (46, 69)      62 (52, 70)
  Age-groups (years)                                                                                                                                                                                                        
   30 to \<50                                                         22 611 (21)      2026 (12)        2728 (37)          124 (22)                  41 (11)            128 (43)          49 (21)          28 (830)         27 735 (21)
   50 to \<70                                                         58 184 (55)      7835 (47)        3050 (42)          291 (53)                  182 (51)           143 (48)          116 (50)         43 (47)          69 844 (53)
   \>70                                                               25 629 (24)      6842 (41)        1515 (21)          138 (25)                  135 (38)           24 (8)            66 (29)          21 (23)          34 370 (26)
  Year of study inclusion                                                                                                                                                                                                   
   2005--2008                                                         37 692 (35)      13 433 (80)      3702 (51)          181 (33)                  123 (34)           5 (2)             174 (75)         53 (58)          55 363 (42)
   2009--2012                                                         68 732 (65)      3270 (20)        3591 (49)          372 (67)                  235 (66)           290 (98)          57 (25)          39 (42)          76 586 (58)
  Marital status                                                                                                                                                                                                            
   Married                                                            64 123 (61)      9630 (59)        4062 (58)          322 (59)                  214 (60)           196 (66)          157 (69)         59 (64)          78 763 (60)
   Never married                                                      13 404 (13)      1271 (8)         1211 (17)          85 (16)                   34 (10)            55 (19)           13 (6)           10 (11)          16 083 (12)
   Divorced                                                           15 457 (15)      2150 (13)        1080 (15)          85 (16)                   46 (13)            32 (11)           22 (10)          17 (18)          18 889 (14)
   Widowed                                                            12 561 (12)      3269 (20)        701 (10)           55 (10)                   60 (17)            12 (4)            36 (16)          6 (7)            16 700 (13)
  CCI score                                                                                                                                                                                                                 
   Low (score of 0)                                                   75 550 (71)      10 224 (61)      3953 (54)          385 (70)                  202 (56)           207 (70)          154 (67)         54 (59)          90 729 (69)
   Medium (scores of 1--2)                                            25 957 (24)      5035 (30)        2076 (28)          134 (24)                  110 (31)           72 (24)           59 (26)          28 (30)          33 471 (25)
   High (score ≥3)                                                    4917 (5)         1444 (9)         1264 (17)          34 (6)                    46 (13)            16 (5)            18 (8)           10 (11)          7749 (6)
  Diabetes complications                                                                                                                                                                                                    
   No complications                                                   77 981 (73)      10 968 (66)      5024 (69)          417 (75)                  204 (57)           237 (80)          168 (73)         71 (77)          95 070 (72)
   Microvascular                                                      6422 (6)         1423 (9)         729 (10)           33 (6)                    31 (9)             16 (5)            22 (10)          6 (7)            8682 (7)
   Macrovascular                                                      22 021 (21)      4312 (26)        1540 (21)          103 (19)                  123 (34)           42 (14)           41 (18)          15 (16)          28 197 (21)
  Alcoholism-related conditions                                       2651 (2)         595 (4)          742 (10)           12 (2)                    17 (5)             4 (2)             10 (4)           3 (3)            4034 (3)
  Hospital-diagnosed obesity                                          9566 (9)         602 (4)          528 (7)            46 (8)                    28 (8)             79 (27)           7 (3)            17 (18)          10 873 (8)
  Hospital outpatient follow-up in first year after study inclusion   16 463 (15)      3502 (21)        1695 (23)          86 (16)                   62 (17)            18 (6)            33 (14)          11 (12)          21 870 (17)
  Therapy change during follow-up                                     30 845 (29)      9977 (60)        2353 (32)          259 (47)                  173 (48)           48 (16)           135 (58)         41 (45)          43 831 (33)
  Therapy change within 1-year                                        16 530 (16)      3618 (22)        1752 (24)          140 (25)                  122 (34)           31 (11)           62 (27)          23 (25)          22 278 (17)
  Therapy change within 2 years                                       21 877 (21)      5581 (33)        1970 (27)          184 (33)                  147 (41)           45 (15)           86 (37)          33 (36)          29 923 (23)
  Number of patients with HbA~1c~ measurement                         27 200 (56)      4576 (59)        1649 (61)          164 (64)                  115 (59)           35 (43)           34 (55)          22 (62)          33 795 (56)
  Median % HbA~1c~ (IQR)                                              7.1 (6.5, 8.3)   7.6 (6.9, 9.2)   10.1 (7.5, 12.1)   8.3 (7.0, 10.6)           7.0 (6.5, 7.7)     6.4 (6.0, 7.3)    7.1 (6.1, 7.9)   7.0 (5.9, 7.8)   7.2 (6.6, 8.7)
  Other medication use                                                                                                                                                                                                      
   Statins                                                            50 817 (48)      6230 (37)        1522 (21)          230 (42)                  167 (47)           80 (27)           63 (27)          24 (26)          59 163 (45)
   Immunosuppressants                                                 669 (1)          134 (1)          85 (1)             2 (\<1)                   3 (1)              4 (1)             2 (1)            5 (5)            904 (1)
   Corticosteroids                                                    3825 (4)         1163 (7)         1044 (14)          20 (4)                    21 (6)             11 (4)            15 (6)           6 (7)            6105 (5)

\*Parentheses contain percentages unless otherwise specified.

CCI, Charlson comorbidity index; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin.

### Bias and sensitivity analyses {#s3c1}

Increased body mass index (BMI) and tobacco smoking may be associated with type 2 diabetes, choice of diabetes therapy and infection risk. As we had data only on hospital-diagnosed obesity and tobacco-related diseases, and no detailed data on smoking or BMI, we computed externally adjusted estimates of unmeasured obesity (BMI ≥30 kg/m^2^) and smoking, respectively, and compared them with our crude estimates, to assess the proportion of effect possibly explained by obesity or smoking alone, using the array approach as presented by Schneeweiss:[@R20]

where caHR is the obesity-adjusted HR, aHR the crude rate ratio observed in our study, Pc0 the proportion of patients with obesity in the reference (metformin) group (estimated at 0.49 in the study period based on the study by Ulrichsen *et al*),[@R21] Pc1 the proportion of patients with obesity in the exposed group (for insulin, 0.19; for sulfonylurea, 0.26)[@R21] and HRcd is the expected rate ratio of infection related to obesity (1.5 for hospital-treated infections and 1.23 for community-based antibiotic use).[@R16] Similarly, we computed externally adjusted estimates for tobacco smoking (Pc0=0.22, Pc1 for insulin=0.26, Pc1 for sulfonylurea=0.30, HRcd for hospital-treated infection=4.1 and HRcd for antibiotic use=1.17).[@R21] Additionally, using a rule-out approach,[@R20] we estimated how strongly a single unmeasured binary confounder (eg, BMI, smoking) would need to be associated with the choice of GLD and infection to fully explain our adjusted results. We repeated this sensitivity analysis for the observed lower limit of the 95% CI of the adjusted HR. We describe the details of the methods and the choice of parameter in online [supplementary appendix](#SM2){ref-type="supplementary-material"} 2. Finally, for a subcohort of our study population (n=33 795), we had additional information on latest glycated haemoglobin (HbA~1c~) level before GLD initiation (baseline HbA~1c~). We repeated the analyses for this subcohort including baseline HbA~1c~ categories (reference category: 5.5%--6.5%) as an additional confounder in the fully adjusted model.
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We used SAS software (V.9.1.3; SAS Institute, Cary, North Carolina, USA) for data management. Analyses were carried out using STATA V.12 (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, Texas, USA: StataCorp LP). The study was approved by the Danish Data Protection Agency (record numbers 2012-41-0793 and 2013-41-1924).

Results {#s3}
=======

Cohort characteristics {#s3a}
----------------------

Of the 131 949 type 2 diabetes patients receiving their first antidiabetic medication, 106 424 (81%) started with metformin, 16 703 (13%) started with sulfonylurea and 7293 (6%) started with insulin. Only 1529 (\<1%) individuals used one of the other GLDs as their initial drug ([table 1](#BMJOPEN2016011523TB1){ref-type="table"}). In our study cohort, 56% (74 391) were men and the median age at inclusion was 62 years (IQR 52--70 years). Compared with type 2 diabetes patients who used metformin as their first drug, sulfonylurea initiators were older (median age 67 years vs 62 years), more likely to be enrolled before 2008 (80% vs 35%), more likely to change therapy within 1 or 2 years (22% and 33% vs 16% and 21%, respectively) and more likely to have comorbidities (39% vs 29%), diabetes-related macrovascular complications (26% vs 21%) or alcoholism-related conditions (4% vs 2%) ([table 1](#BMJOPEN2016011523TB1){ref-type="table"}). Patients who initiated their therapy with sulfonylurea also had less hospital-diagnosed obesity (4% vs 9%), and were less likely to be using statins at the time of GLD initiation (37% vs 48%).

Insulin initiators were younger (median age 56 vs 62 years); more likely to have been included in the study before 2008 (51% vs 35%); more likely to have comorbidities (45% vs 29%), microvascular complications (10% vs 6%) and alcoholism-related conditions (10% vs 2%); less likely to be using statins (21% vs 48%); and more likely to have changed their therapy within 1 or 2 years (24% and 27% vs 16% and 21%, respectively) than metformin initiators ([table 1](#BMJOPEN2016011523TB1){ref-type="table"}).

Rates of community-based antibiotic use and hospital-treated infections {#s3b}
-----------------------------------------------------------------------

During 218 032 PYAR, we identified 78 847 events (60% of all patients), yielding an IR of 361.8 per 1000 PYAR (95% CI 359.2 to 364.3). The IRs of community-based antibiotic use were higher in patients who initiated their treatment with insulin compared with those who initiated with sulfonylurea or metformin (see online [supplementary table](#SM3){ref-type="supplementary-material"} S1). We identified 20 308 (15%) initial-onset hospital-treated infection events during 395 171 PYAR, yielding an overall IR of 51.4 per 1000 PYAR (95% CI 50.7 to 52.1). IRs of hospital-treated infections were highest in patients who initiated their treatment with insulin, followed by patients who initiated with sulfonylurea and metformin (see online [supplementary table](#SM3){ref-type="supplementary-material"} S1). Cumulative rates of community-based antibiotic prescriptions and hospital-treated infections within the first 4 years in patients who initiated their treatment with metformin, sulfonylurea or insulin are illustrated in [figure 1](#BMJOPEN2016011523F1){ref-type="fig"}. The figure shows that infection rates increased most sharply shortly after GLD treatment initiation. The unadjusted curves for the three treatment modalities diverged early during follow-up, with insulin initiators experiencing more infections than sulfonylurea initiators throughout follow-up, and sulfonylurea initiators experiencing more infections than metformin initiators (log-rank test for equality of survival function between the three exposure groups, p\<0.00001 for both outcomes) ([figure 1](#BMJOPEN2016011523F1){ref-type="fig"}).

![Kaplan-Meier curves showing cumulative rates of community-based antibiotic prescriptions and hospital-treated infections as percentages within the first 4 years following treatment initiation with metformin, sulfonylurea or insulin.](bmjopen2016011523f01){#BMJOPEN2016011523F1}
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Community-based antibiotic use {#s3c}
------------------------------

Compared with patients who initiated their treatment with metformin, the crude risk of subsequent community-based antibiotic prescriptions was increased in patients who initiated treatment with sulfonylurea (crude HR 1.06, 95% CI 1.04 to 1.08). The HR remained stable even after adjusting for age and sex (HR 1.05, 95% CI 1.03 to 1.07), but reduced to 1.02 (95% CI 1.01 to 1.04) in the fully adjusted model ([table 2](#BMJOPEN2016011523TB2){ref-type="table"}). For specific antibiotic groups, patients who initiated antidiabetic treatment with sulfonylurea were at increased risk of treatment for infection with azithromycin (adjusted HR 1.10, 95% CI 1.03 to 1.17), quinolones (adjusted HR 1.43, 95% CI 1.12 to 1.84), antibiotics used to treat urinary tract infection (UTI) (adjusted HR 1.07, 95% CI 1.03 to 1.11) and other broad-spectrum antibiotics (adjusted HR 1.07, 95% CI 1.03 to 1.11) ([figure 2](#BMJOPEN2016011523F2){ref-type="fig"} and see online [supplementary table](#SM3){ref-type="supplementary-material"} S2).

###### 

HRs of infection associated with initial use of glucose-lowering drugs in patients with type 2 diabetes, according to drug category

                                   Metformin         Sulfonylurea          Insulin               Fixed drug combinations   DPP-4 inhibitors      GLP-1 analogues       Meglitinides          Other
  -------------------------------- ----------------- --------------------- --------------------- ------------------------- --------------------- --------------------- --------------------- ---------------------
  Community-based antibiotic use                                                                                                                                                             
   Number of events                61 055            12 462                4434                  317                       213                   146                   183                   64
   Crude HR (95% CI)               1.00 (referent)   1.06 (1.04 to 1.08)   1.13 (1.09 to 1.16)   1.03 (0.92 to 1.15)       1.16 (1.01 to 1.32)   1.31 (1.12 to 1.55)   1.07 (0.92 to 1.24)   1.17 (0.92 to 1.50)
   Model 1\* HR (95% CI)           1.00 (referent)   1.05 (1.03 to 1.07)   1.18 (1.15 to 1.22)   1.06 (0.95 to 1.18)       1.16 (1.01 to 1.32)   1.29 (1.09 to 1.51)   1.06 (0.92 to 1.23)   1.17 (0.92 to 1.50)
   Model 2† HR (95% CI)            1.00 (referent)   1.02 (1.00 to 1.04)   1.04 (1.01 to 1.07)   1.04 (0.93 to 1.16)       1.11 (0.97 to 1.27)   1.20 (1.02 to 1.41)   1.01 (0.87 to 1.17)   1.07 (0.84 to 1.36)
  Hospital-treated infections                                                                                                                                                                
   Number of events                13 949            4350                  1785                  74                        53                    18                    61                    18
   Crude HR (95% CI)               1.00 (referent)   1.41 (1.36 to 1.46)   1.96 (1.87 to 2.06)   1.06 (0.85 to 1.34)       1.28 (0.98 to 1.68)   0.85 (0.54 to 1.36)   1.40 (1.09 to 1.79)   1.29 (0.81 to 2.05)
   Model 1\* HR (95% CI)           1.00 (referent)   1.20 (1.16 to 1.24)   2.28 (2.17 to 2.39)   1.05 (0.84 to 1.33)       1.14 (0.87 to 1.49)   1.05 (0.66 to 1.66)   1.34 (1.04 to 1.72)   1.28 (0.81 to 2.03)
   Model 2† HR (95% CI)            1.00 (referent)   1.12 (1.08 to 1.16)   1.63 (1.54 to 1.72)   1.03 (0.82 to 1.30)       1.05 (0.80 to 1.38)   0.93 (0.58 to 1.47)   1.27 (0.98 to 1.64)   1.04 (0.66 to 1.65)

\*Model 1 adjusted for age and sex.

†Model 2 adjusted for age, sex, comorbidity (CCI score), hospital-diagnosed obesity, alcoholism-related conditions, marital status, microvascular and macrovascular diabetes complications not included in the CCI, diabetes duration, concurrent use of statins/corticosteroids/immunosuppressive drugs and calendar period of study inclusion.

DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1.

![Adjusted HRs of specific antibiotic therapies associated with pharmacotherapy initiation with sulfonylureas versus metformin (shown as blue diamonds) and insulin versus metformin (shown as red squares), in patients with type 2 diabetes. M, S and I denote total number or hospital-treated infections in metformin, sulfonylurea and insulin initiators, respectively.](bmjopen2016011523f02){#BMJOPEN2016011523F2}

Similarly, the risk of community-based antibiotic use in patients who initiated their treatment with insulin decreased from 1.13 (95% CI 1.09 to 1.16) to 1.04 (95% CI 1.01 to 1.07) in the fully adjusted model ([table 2](#BMJOPEN2016011523TB2){ref-type="table"}). For specific antibiotic groups, insulin initiators had increased risks of subsequent treatment of infections with quinolones (adjusted HR 4.36, 95% CI 3.36 to 5.65), cephalosporins (adjusted HR 4.65, 95% CI 2.16 to 10.01), dicloxacillin/flucloxacillin (adjusted HR 1.16, 95% CI 1.09 to 1.24) and with antibiotics used to treat UTI (adjusted HR 1.17, 95% CI 1.11 to 1.24) ([figure 2](#BMJOPEN2016011523F2){ref-type="fig"} and see online [supplementary table](#SM3){ref-type="supplementary-material"} S2).

In sensitivity analyses for sulfonylurea versus metformin, external adjustment for unmeasured obesity (lower with sulfonylurea) changed the crude HR from 1.06 to 1.11 and for smoking (higher with sulfonylurea) changed the crude HR from 1.06 to 1.05, respectively. For insulin versus metformin, external adjustment for unmeasured obesity changed the crude HR from 1.13 to 1.20 and for smoking changed the crude HR from 1.13 to 1.12, respectively. The rule-out sensitivity analysis suggested that had we been able to account for obesity, we would likely have observed an association of antibiotic use with sulfonylurea or insulin compared with metformin that was stronger than we observed, as obesity is more prevalent among metformin users than the other treatment (see online [supplementary appendix](#SM2){ref-type="supplementary-material"} 2 for details). In contrast, had we been able to account for more smoking in sulfonylurea or insulin compared with metformin users, this might have nullified our weakly increased antibiotic HRs. For example, if smoking were 1.3-fold more prevalent among sulfonylurea than metformin users, the relatively likelihood of being prescribed antibiotics would have to be about 50% greater in those who smoke for the HR to be ≤1, which is plausible from findings in the literature[@R21] (see online [supplementary figure](#SM2){ref-type="supplementary-material"} S1.4 in appendix 2).

We performed further analyses on the subcohort of patients with baseline HbA~1c~ information. Compared with those who initiated their treatment with metformin, patients first treated with sulfonylurea and insulin had adjusted HRs of community-based antibiotic use of 1.05 (95% CI 1.01 to 1.10) and 1.03 (95% CI 0.96 to 1.11), respectively (vs 1.02, 95% CI 1.00 to 1.04, and 1.04, 95% CI 1.01 to 1.07 in the full cohort). After additional adjustment for baseline HbA~1c~, the HRs did not change for sulfonylurea initiators (adjusted HR 1.05, 95% CI 1.01 to 1.10), but increased slightly for insulin initiators (adjusted HR 1.08, 95% CI 1.00 to 1.17) (see online [supplementary table](#SM3){ref-type="supplementary-material"} S3).

The HRs were not increased for the rest of the rarer GLD categories ([table 2](#BMJOPEN2016011523TB2){ref-type="table"}). For GLDs other than sulfonylurea and insulin, the HRs and number of infections (if ≤4) treated with specific antibiotic groups are provided in online [supplementary table](#SM3){ref-type="supplementary-material"} S2.

Hospital-treated infections {#s4d}
---------------------------

Compared with patients who initiated treatment with metformin, the risk of hospital-treated infections was higher in patients who initiated treatment with sulfonylurea (HR 1.41, 95% CI 1.36 to 1.46). The HR was reduced to 1.20 (95% CI 1.16 to 1.24) in Model 1 and further reduced to 1.12 (95% CI 1.08 to 1.16) in fully adjusted Model 2 ([table 2](#BMJOPEN2016011523TB2){ref-type="table"}). Patients who initiated their treatment with sulfonylurea had increased risk of hospitalisation for viral infections (adjusted HR 1.70, 95% CI 1.40 to 2.07), fungal infections (adjusted HR 1.45, 95% CI 1.15 to 1.83), intra-abdominal infections (adjusted HR 1.27, 95% CI 1.14 to 1.41), bacterial infections (adjusted HR 1.27, 95% CI 1.07 to 1.50), UTI (adjusted HR 1.08, 95% CI 1.01 to 1.17), pneumonia (adjusted HR 1.19, 95% CI 1.12 to 1.26) and septicaemia (adjusted HR 1.12, 95% CI 1.02 to 1.24) compared with those who initiated treatment with metformin ([figure 3](#BMJOPEN2016011523F3){ref-type="fig"} and see online [supplementary table](#SM3){ref-type="supplementary-material"} S4).

![Adjusted HRs of specific hospital-treated infections associated with pharmacotherapy initiation with sulfonylureas versus metformin (shown as blue diamonds) and insulin versus metformin (shown as red squares), in patients with type 2 diabetes. M, S and I denote total number or hospital-treated infections in metformin, sulfonylurea and insulin initiators, respectively.](bmjopen2016011523f03){#BMJOPEN2016011523F3}

The risk of hospital-treated infections was twice as high in patients initiating treatment with insulin compared with metformin initiators (HR 1.96, 95% CI 1.87 to 2.07), and the association strengthened after adjusting for age and sex (HR 2.28, 95% CI 2.17 to 2.39). After inclusion of other confounders, the HR decreased to 1.63 (95% CI 1.54 to 1.72) in the full model ([table 2](#BMJOPEN2016011523TB2){ref-type="table"}). Type 2 diabetes patients who initiated treatment with insulin had a greater risk of hospitalisation for nearly all examined infections in particular fungal infections (adjusted HR 2.45, 95% CI 1.82 to 3.29), tuberculosis (adjusted HR 2.39, 95% CI 1.11 to 5.14), infections of the heart and blood vessels (adjusted HR 2.13, 95% CI 1.21 to 3.75) and septicaemia (adjusted HR 2.10, 95% CI 1.84 to 2.40), compared with patients who initiated treatment with metformin ([figure 3](#BMJOPEN2016011523F3){ref-type="fig"} and see online [supplementary table](#SM3){ref-type="supplementary-material"} S4).

In sensitivity analyses for sulfonylurea versus metformin, external adjustment for unmeasured obesity changed the crude HR from 1.41 to 1.55, while external adjustment for smoking decreased the HR to 1.23, respectively. For insulin versus metformin, external adjustment for unmeasured obesity (lower with insulin) increased the crude HR from 1.96 to 2.23 and decreased to 1.83 after external adjustment for smoking (more with insulin). The rule-out approach of sensitivity analyses illustrated that for hospital-treated infections, neither obesity nor smoking could completely explain the observed association in our study (see online [supplementary appendix](#SM2){ref-type="supplementary-material"} 2 for details). For example, if obesity were 1.6-fold more frequent among sulfonylurea users than metformin users, the relative likelihood of hospital-treated infections would have to be increased by a factor of three or more to explain our findings fully, if no increased risk actually existed, which is unlikely based on available literature[@R21] (see online [supplementary figure](#SM2){ref-type="supplementary-material"} S2.2 in appendix 2).

In the subcohort with available baseline HbA~1c~ information, pre-treatment HbA~1c~ decreased from insulin to sulfonylurea to metformin initiators; however, baseline HbA~1c~ per se was not a strong predictor of infection risk (data not shown). When using treatment initiation with metformin as the comparator, adjusted HRs of hospital-treated infection associated with sulfonylurea and insulin initiation in the subcohort were 1.17 (95% CI 1.08 to 1.26) and 1.88 (95% CI 1.69 to 2.1), respectively (vs 1.12 and 1.63 in the full cohort). Additional adjustment for baseline HbA~1c~ did not change the adjusted HR for sulfonylurea initiators (adjusted HR 1.17, 95% CI 1.08 to 1.26), and increased it slightly for insulin initiators (adjusted HR 1.96, 95% CI 1.73 to 2.22) (see online [supplementary table](#SM3){ref-type="supplementary-material"} S3).

Few episodes of infection occurred in patients taking medication in the remaining small GLD categories, and we did not detect a clear difference compared with metformin ([table 2](#BMJOPEN2016011523TB2){ref-type="table"}). For GLDs other than sulfonylurea and insulin, the HRs and number of hospital contacts (if ≤4) for specific infections are provided in online [supplementary table](#SM3){ref-type="supplementary-material"} S4.

Discussion {#s5}
==========

In this study of patients with type 2 diabetes treated pharmacologically for the first time, we found high rates of community-based antibiotic treatment and hospitalisations for infection during follow-up. We also found that patients who initiated pharmacotherapy with insulin, and to less extent those who initiated sulfonylurea, were at increased risk of hospital-treated infection compared with those who initiated pharmacotherapy with metformin. In contrast, there was little difference in rates of community-based antibiotic use between initiators of different GLDs.

Our results corroborate findings from the Swedish study that reported an increased risk of hospitalisation for infection among patients who initiated their pharmacotherapy with insulin alone (HR 1.37, 95% CI 1.26 to 1.50) or with other oral GLDs (other than metformin) (HR 1.16, 95% CI 1.04 to 1.28), compared with metformin.[@R9] Furthermore, our results are in line with the observed reduced odds of septicaemia in metformin users versus metformin never users (OR 0.80, 95% CI 0.77 to 0.83) and increased odds in sulfonylurea users versus sulfonylurea never users (OR 1.06, 95% CI 1.03 to 1.10) in the nationwide cohort of GLD-treated type 2 diabetes patients from Taiwan.[@R6] Few comparative studies have examined newer second-line GLDs.[@R24] [@R25] Although statistically imprecise, our results are in line with those from a double-blind randomised study of 807 type 2 diabetes patients, in which 3% of patients treated with metformin and 6% of patients treated with DPP-4 inhibitors experienced an upper respiratory tract infection (URTI) event during a follow-up period of 52 weeks (p \>0.05).[@R25] Our results support a recent systematic review and meta-analysis of 19 randomised controlled trials that found no difference in risk of UTI (RR 0.86, 95% CI 0.51 to 1.45) between patients receiving DPP-4 inhibitors and those receiving metformin.[@R24]

Hyperglycaemia may be a risk factor for infections in patients with type 2 diabetes.[@R26] Therefore, GLDs in theory might influence risk of infections via their different glucose-lowering mechanisms and effectiveness. Hyperglycaemia seems to weaken innate immunity via its negative influence on polymorphonuclear neutrophil function and intracellular bactericidal and opsonic activity.[@R31] Insulin is more effective in reducing blood glucose than sulfonylureas and metformin;[@R32] and insulin has been suggested to enhance innate and cell-mediated immunity[@R33] and promote macrophage function.[@R31] [@R34] This contrasts with our observation that insulin initiators had the highest risk of infections. Other non-glycaemic effects of GLDs on the immune system might be at play.[@R31] [@R33] [@R35] It has been suggested that the 5′ AMP-activated protein kinase activation property of metformin facilitates neutrophil-dependent bacterial uptake and killing associated with inhibition of neutrophil activation and chemotaxis.[@R36] [@R37] This mechanism might contribute to the lower risk of infections in patients taking metformin versus insulin or sulfonylureas.[@R9] Apart from the inhibitory effect of sulfonylureas on inflammasome assembly, evidence is sparse on their association with immune regulation.[@R35] Thus, while the mechanisms underlying the association of different GLDs with infection remain unclear,[@R38] our results support metformin as the preferred first-line drug in treatment algorithms from the point of view of infections.

The main strengths of our study are its population-based design, the large nationwide cohort of patients with type 2 diabetes and virtually no loss to follow-up (\<1%). The use of high-quality medical databases to identify infections treated in the community and in the hospital setting ensured inclusion of nearly all diagnosed infections.

Nonetheless, observational studies of the comparative effects of diabetes drugs have several major methodological challenges.[@R39] Therefore, our results for different therapies should be interpreted with caution, bearing in mind the limitations of this routine registry-based study. A main limitation was lack of accurate data on clinical severity of diabetes, which might have led to residual confounding by indication.[@R40] Nevertheless, increased clinical severity of type 2 diabetes (including complications such as early signs of renal disease, or indicators of less insulin production), other contraindications to metformin and/or anticipated worse glucose derangement may have led physicians to initiate treatment with sulfonylurea and particularly insulin instead of metformin. This may be supported by our observation that sulfonylurea and insulin initiators had more subsequent therapy shifts than metformin initiators, possibly related to glycaemic control problems. However, our regional subcohort analysis suggested that differences in pre-treatment HbA~1c~ (highest with insulin initiation) did not explain observed drug differences. It is also possible that a pre-existing predisposition to infections may have led physicians to choose insulin versus other drugs as initial pharmacotherapy. Furthermore, unmeasured confounding due to combination of other factors such as those related to unhealthy lifestyle and less social support might have influenced the risk of infections. Our sensitivity analyses suggested that the observed weak associations between non-metformin GLDs and increased antibiotic use may have been explained by differences in smoking, although on the other hand, differences in BMI and baseline HbA~1c~ may have led to an underestimation of the associations.

Our results for infections treated in the hospital suggest either increased severity of infections associated with specific GLDs or a lower threshold for hospitalising a patient with a given infection, for example, due to anticipated problems with glycaemic control or more comorbidity/frailty among patients in these treatment groups (surveillance bias). However, since we observed consistent results for hospitalisations for severe infections, such as septicaemia, for which all patients are likely to receive inpatient care, it is unlikely that our results can be explained by increased surveillance alone. As well, the initial GLD therapy choice may be altered, which may lead to increasing exposure misclassification with longer follow-up periods. However, we observed that less than one-quarter of our patients changed therapy within the first year of starting treatment with an antidiabetic drug. Changes were most likely for patients treated with insulin and sulfonylurea and thus unlikely to explain their increased infection risk compared with metformin users.

In conclusion, the present study provides evidence that rates of infection are high in type 2 diabetes patients during early treatment, and that pharmacotherapy initiation with metformin may be associated with reduced risk of hospital-treated infections, compared with other GLDs.
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